Objectives: Development of a novel MALDI-TOF MS-based method for the rapid detection of ESBL-producing Enterobacteriaceae.
Introduction
Antibiotic resistance, currently one of the most common healthcare problems worldwide, has increased in recent years. [1] [2] [3] [4] One approach that shortens the time-to-result for antibiotic susceptibility testing is the use of MALDI-TOF MS. [5] [6] [7] [8] The aim of this study was to assess the performance of the MALDI-TOF Biotyper Compass software in the Selective Testing of Antibiotic Resistance b-lactamase (MBT STAR-BL, Bruker Daltonik GmbH, Germany) module for detecting b-lactam resistance using ceftriaxone as a resistance marker in a series of 100 clinical isolates.
Materials and methods

Evaluation of the MBT STAR-BL software for detecting b-lactam resistance
As a preliminary step, we evaluated the performance of the automated MBT Compass software in the STAR-BL module (Bruker Daltonik) for detecting b-lactam resistance. The terms resistant and susceptible are used here to refer to microbiological resistance and are related to the genotypic characterized pattern. This method yields the logRQ value (ratio of hydrolysis), 9 in contrast to the FlexAnalysis 3.3 software (Bruker Daltonik), which is based on monitoring hydrolysis of the antibiotic by visual inspection of the mass peaks corresponding to the hydrolysed and non-hydrolysed forms of the antibiotic.
For the evaluation, we tested 11 isogenic Escherichia coli control strains using cefotaxime and ceftazidime as antibiotic markers and clavulanic acid, to rule out the presence of non-ESBL mechanisms, as previously described by our group. 7 The evaluation included analysis of the sensitivity, specificity and turnaround time of the assay (Table S1 , available as Supplementary data at JAC Online).
The resistance assay was performed as described by Sparbier et al.
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Briefly, for analysis of plated bacteria, a 1 lL loop of bacteria was resuspended in 50 lL of antibiotic solution containing cefotaxime (Sigma-Aldrich, Germany; 0.50 mg/mL) and ceftazidime (Sigma-Aldrich; 0.25 mg/mL).
antibiotics is best, in terms of sensitivity, specificity and turnaround time, for detecting b-lactamase activity against the above-mentioned isogenic E. coli control strains in the automated MBT Compass software in the STAR-BL module (Table 1 and Figures S1 and S2 ). Bacterial isolates were evaluated simultaneously in different solutions of reaction buffer (10 mM NH 4 HCO 3 /0.005% SDS at pH 8.0) 9 containing cefotaxime (Sigma-Aldrich; 0.50 mg/mL), ceftazidime (Sigma-Aldrich; 0.25 mg/mL), ceftriaxone (Sigma-Aldrich; 0.50 mg/mL), cefpodoxime (Sigma-Aldrich; 0.25 mg/mL) and cefepime (Sigma-Aldrich; 0.50 mg/mL). Parallel evaluations with the antibiotics plus clavulanic acid (Sigma-Aldrich; 0.50 mg/mL) were performed to confirm the presence of ESBL mechanisms. Measurements were made 30 and 60 min after addition of the bacteria to the antibiotic solutions.
Detection of b-lactamase activity in clinical isolates
A total of 100 previously characterized non-repeat Enterobacteriaceae isolates were tested. Eighty-five of these carried a b-lactamase (3 bla TEM-1 , 6 bla SHV-12 , 2 bla OXA-1 , 5 bla K-1 , 6 bla CMY-2 , 1 bla CMY-10 , 2 bla FOX-4 , 1 bla FOX-8 , 4 bla DHA-6 , 2 bla DHA-7 , 12 bla CTX-M-14 , 9 bla CTX-M-15 and 32 bla CTX-M-32 ) and 15 isolates did not carry a resistance enzyme ( Figure 1 ). Molecular characterization was performed by PCR and further sequencing of the isolates selected for b-lactam susceptibility testing. 10, 11 The following isolates were identified: 1 Enterobacter cloacae, 5 Klebsiella oxytoca, 26 Klebsiella pneumoniae and 68 E. coli.
For the MALDI-TOF MS assay, isolates were previously grown overnight at 37 C in Trypticase Soy Agar with 5% sheep blood (TSA, Becton Dickinson). Hydrolysis of ceftriaxone (Sigma-Aldrich; 0.5 mg/mL; 10 mM NH 4 HCO 3 / 0.005% SDS at pH 8.0) and ceftriaxone with clavulanic acid (0.5 mg/mL) was evaluated after incubation of the cultures for 30 min at 37 C under agitation. All tests were performed in the presence of a positive (POSC isolate) and negative (NEGC isolate) control (Table S2 ). The stability of the antibiotics was assessed before the measurement in every assay performed.
MALDI-TOF MS analysis
For MALDI-TOF MS measurements aimed at detecting b-lactam resistance, duplicate samples (1 lL) of the supernatant obtained after centrifugation of the incubated bacteria with the antibiotic solution were spotted directly onto a polished steel MALDI target plate. Dried spots were overlaid with 1 lL a-cyano-4-hydroxy-cinnamic acid (HCCA). Once the matrix was dry, mass spectra were acquired on a microflex LT/SH bench-top mass spectrometer (Bruker Daltonik). The FlexControl 3.3 software was used for qualitative interpretation and the STAR-BL module was used for automated interpretation of spectra.
In the STAR-BL module, the software automatically calculates the logRQ value (which indicates the rate of hydrolysis) for the different antibiotics. The logRQ is calculated as the area under the curve between the mass peaks corresponding to the hydrolysed products divided by the non-hydrolysed antibiotic. LogRQ values were normalized according to defined negative and positive control strains. Normalized logRQ values below 0.2 represent negative strains and values above 0.4 indicate b-lactamase activity. Normalized logRQ values between 0.2 and 0.4 represent an ambiguous hydrolysis pattern that requires further testing (retesting or prolonging incubation time). Positive and negative controls must show a difference of at least 0.5 in terms of logRQ in all assays for confirmation of the results. Oviaño et al.
Results and discussion
microbiological concepts of susceptibility and resistance. Using the automated software, we obtained an average of 41% more positive results in detecting cefotaxime and ceftazidime hydrolysis for the same incubation time compared with using qualitative interpretation of spectra (Table S1 ). For cefotaxime, the greatest increase in the positive results was observed after incubation of the isolates for 60 min, whilst for ceftazidime it was found at 120 min. Regarding the turnaround time for positive results of the automated assay for cefotaxime hydrolysis detection, reducing the incubation time relative to that used in qualitative interpretation of spectra (i.e. 60 min) yielded false negative results. This is due to the lack of evident hydrolysis, after 30 min, with isolates carrying resistance mechanisms such as bla CTX-M-15 and bla DHA-6 and the partial hydrolysis of bla TEM-29, bla CMY-2 and bla CTX-M-14. However, incubation of the cultures for 60 min provided more sensitive results with the automated software, as both ESBL and AmpC (bla CMY-2, bla DHA-1 and bla DHA-6 ) resistance mechanisms were detected. By contrast, no positive results were obtained with qualitative interpretation of the spectra. Use of the logRQ value was especially important when the mass peaks yielded by the antibiotic and its hydrolysed product appeared in the same spectrum, as the susceptibility result was therefore unclear and the only way of predicting whether the isolate was susceptible or resistant was to use a longer incubation time. The MBT STAR-BL software reduces the intra-and inter-observer-related variability of the assay, thus providing standardized results, which simplifies its use in the laboratory and supports application of the technique by users who are not trained in MS techniques.
Ceftriaxone is the best antibiotic marker in MS for detection of b-lactam resistance mediated by b-lactamase production The mass peaks of cefotaxime and ceftazidime have been described by Sparbier et al. 5 Structural determination of ceftriaxone, cefpodoxime and cefepime has not yet been reported; therefore analysis of experimental data for the antibiotics by MALDI-TOF MS has been performed (Table 1 and Figure S1 ). Our preliminary studies with cefotaxime, ceftazidime and cefpodoxime, which are widely recommended for phenotypic ESBL screening, indicated that these drugs are less sensitive markers in MS. The isolate carrying bla TEM-1 did not hydrolyse any antibiotic tested, except cefepime. The other resistance mechanisms were considered to be responsible for hydrolysis of the antibiotics. Ceftriaxone yielded 70% more positive results than cefotaxime, 80% more than ceftazidime and 20% more than cefpodoxime, with 100% specificity for detecting AmpC and ESBL resistance mechanisms. Analysis of the results obtained with cefepime revealed 100% sensitivity but only 27% specificity in detecting ESBL resistance mediated by b-lactamases, as isolates carrying bla TEM-1, bla SHV-12, bla TEM-29, bla FOX-4, bla CMY-2, bla DHA-1, bla DHA-6 and bla DHA-7 unexpectedly hydrolysed the antibiotic. Therefore, we ruled out use of cefepime as a useful antibiotic in terms of MS and considered ceftriaxone for either detecting ESBL or AmpC enzymes by MALDI-TOF MS; an incubation time of 30 min proved sufficient to produce reliable results.
Clinical validation of the detection of b-lactamases by MALDI-TOF MS
Spectra were analysed according to the algorithm described above and the results are displayed in a scatter plot (Figure 1 
Conclusions
In conclusion, MALDI-TOF MS is an outstanding tool for the detection of b-lactamase resistance mediated by b-lactamases in clinical samples. The method is not time consuming and analytical results can be obtained within 30-60 min, thereby facilitating the implementation of the technique in microbiological laboratories and allowing early and suitable antimicrobial therapy. 12 
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